Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.

NCT01705002 is registered in ClinicalTrials.gov with Lipomedix Pharmaceuticals Inc. as lead sponsor.

NCT NCT01705002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01705002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.
Lead sponsor
Lipomedix Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2012
Completion date
June 30, 2018
Enrollment
88 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, metastatic colorectal cancer (mcrc), solid tumor